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How to obtain Pt(IV) complexes suitable for the conjugation to 
nanovectors from the oxidation of [PtCl(terpyridine)]+. 
E. Gabano,a E. Perin,a C. Fielden,b J. A. Platts,b A. Gallina,a B. Rangone,a M. Ravera.a,* 
Oxidation of [Pt(II)Cl(terpy)]+ (teƌpǇ = Ϯ,Ϯ’:ϲ’,Ϯ͟-terpyridine) has been attempted with several oxidizing agents and in different 
experimental conditions in order to obtain a Pt(IV) complex suitable for the conjugation to nanovectors to be used in drug 
delivery targeting for anticancer therapy. The best compromise in terms of yield and purity of the final complex was obtained 
by microwave-assisted reaction at 70 °C in 50% aqueous H2O2 for 2 h. Under these conditions the quantitative formation of 
[Pt(IV)Cl(OH)2(terpy)]+ was observed. Subsequent synthetic steps were i) functionalization of [Pt(IV)Cl(OH)2(terpy)]+ in the axial 
position with succinic anhydride to obtain [Pt(IV)Cl(OH)(succinato)(terpy)]+, and ii) reaction of the latter with nonporous silica 
nanoparticles (SNPs) with an external shell containing primary amino groups to obtain a nanovector able to transport the 
Pt(IV) antitumor prodrug in form of conjugate Pt-SNP. Finally, the antiproliferative activity and cell accumulation of 
[Pt(II)Cl(terpy)]+, [Pt(IV)Cl(OH)2(terpy)]+, and Pt-SNP conjugate were measured on three cancer cell lines. Despite highly 
effective accumulation of Pt-SNP into cells, a modest increase in activity was observed with respect to the molecular species. 
Further experiments showed that the Pt-SNP conjugate can release [Pt(II)Cl(terpy)]+ upon reduction, but this metabolite may 
undergo hydrolysis, and the resulting aquo complex could coordinate once again the free amino groups of the SNPs. In the 
resulting tetraamine form, the Pt(II) complex conjugated to the SNPs cannot completely exert its antiproliferative activity. 
Introduction 
The traditional structure-activity relationship (SAR) rules for 
antitumor Pt(II) complexes indicated that triamine compounds 
are scarcely cytotoxic.1-3 In fact most of these complexes have 
very low potency because, in contrast to Pt-diamine compounds 
like cisplatin (cis-[PtCl2(NH3)2]), they can only bind DNA in a 
monofunctional way.4 However, some cis-[Pt(A)(Cl)(NH3)2]+ 
cations, where A is a derivative of pyridine, pyrimidine, purine, 
or aniline, inhibit DNA synthesis, block DNA polymerases and 
are active against in vivo tumor models.5, 6 In particular, 
transcription is strongly inhibited by cis-[PtCl(NH3)2(py)]+ (py = 
pyridine), whereas adducts of [PtCl(dien)]+ (dien = 
diethylenetriamine), which do not have the same steric 
hindrance, are less effective. Although the block of transcription 
by cisplatin and cis-[PtCl(NH3)2(py)]+ is similar, repair of adducts 
formed by the latter is reduced so that they persist longer than 
those of cisplatin,7 and the activity of triamine complexes seems 
to be related to their steric hindrance.8 Moreover, Lippard et al. 
showed that, among several monofunctional platinum(II) 
complexes, phenanthriplatin (cis-
[PtCl(NH3)2(phenanthridine)]+) displays significant antitumor 
properties. Its cellular response is different from cisplatin-like 
drugs because DNA intercalation is associated with 
monodentate binding. The resulting adducts inhibit 
transcription, whereas the low distortion of DNA significantly 
eludes repair. Thus, phenanthriplatin proved to be very 
effective on several cell lines.9-15  
 Recently, triamine (or in general monofunctional) Pt(II) 
complexes have been re-evaluated as anticancer drugs,16 since 
carefully designed ligands allow the resulting Pt compounds to 
bind with DNA in a different manner. This could result in 
alternative cell death mechanisms and/or circumvention of Pt 
resistance. In particular, Pt(II) complexes containing terpyridine 
(teƌpǇ = Ϯ,Ϯ’:ϲ’,Ϯ͟-terpyridine) derivatives, that can be regarded 
as quite bulky triamine complexes,17 are interesting since some 
caŶ iŶteƌcalate iŶto the DNA dupleǆ, ǁith a pƌefeƌeŶce foƌ ϱ’-CG 
sites, due to greater polarity compared to A-T base pairs.18, 19 
The Pt(II)-terpy complexes also interact with four-stranded G-
quadruplex DNA.20-24 G-quadruplex emerged as a promising 
anti-cancer target because their stabilization indirectly inhibits 
the telomerase enzyme. This enzyme is expressed in more than 
85% of human tumors and compensates the loss of telomeres 
at each round of replication, thus contributing to cancer 
survival.25, 26 In another scenario, Pt(II)-terpy complexes were 
found to inhibit the growth of different morphological forms of 
Trypanosoma cruzi and Trypanosoma brucei, the parasitic 
protozoa causative agents of Chagas' disease and African 
trypanosomiasis (sleeping sickness), respectively.27, 28 Finally, 
Pt(II)-terpy derivatives with luminescence properties have been 
studied for bioimaging as DNA staining agents29 and 
biotinylated Pt(II)-ferrocenylterpyridine complexes were also 
tested for targeted photoinduced cytotoxicity.30 
 A strategy to reduce toxicity and improve uptake properties 
of antitumor Pt complexes is to turn them into Pt(IV) prodrugs. 
Such complexes can be reduced in the hypoxic tumor 
environment to the corresponding cytotoxic Pt(II) metabolite 
with loss of axial ligands (activation by reduction). The saturated 
six-coordinated octahedral geometry of Pt(IV) is generally 
characterized by kinetic inertness that minimizes off-target 
effects, thus improving the therapeutic properties and allowing 
oral administration.31-34 In this context, it is interesting to study 
Pt(IV) derivatives of Pt(II)-terpy cations, since only few such 
derivatives have been already reported, where the Pt(II) 
precursor was oxidized with Cl2,35 or [KAuCl4].36 
 A further possibility to improve the activity of a drug is the 
exploitation of drug targeting and delivery (DTD) methods. 
Active DTD uses specific molecular interactions between the 
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drugs and cancer cell or tissue. On the contrary, passive DTD 
takes advantage of the enhanced permeability and retention 
(EPR) effect in tumor tissues, by using functionalized polymers, 
nanoparticles, micelles, liposomes or nanotubes and their 
conjugation with the drugs.37 By this effect, macromolecules 
selectively gather in the tumor interstice, because the tumor 
vessels are highly disordered and swollen with abundant pores 
resulting in enlarged gap junctions between endothelial cells 
and compromised lymphatic drainage.37 Recently, amino-
functionalized silica nanoparticles (NPs) were tested as efficient 
carriers for Pt(IV) prodrugs. Controlled drug release from NPs 
exploits the combination between the unique features of the 
Pt(IV) prodrugs and those of the tumor environment. The in 
vitro/in vivo activation by reduction of the Pt(IV) moiety 
releases the active square planar Pt(II) metabolite, with 
consequent detachment of the axial ligand/s bearing the 
vector/s.34, 38, 39 
 In this paper, the synthesis, characterization and in vitro 
evaluation of Pt(IV)-terpy complexes (Fig. 1) and the 
corresponding SNPs conjugate are described. Interestingly, 
most of the traditional synthetic methods failed to give the 
desired intermediates and microwave-assisted reactions40 had 
to be performed. Such behavior was also theoretically 
investigated with DFT calculations. 
 
Fig. 1. Sketch of the synthesized complexes 1-3 with numbering scheme for the assignment of NMR signals. 
Results and discussion 
Synthesis of Pt(IV) complexes containing terpyridine. 
Complex 1 was synthesized from [PtCl2(4-cod)] (cod = 
cycloocta-1,5-diene) and terpy according to literature 
procedures (see experimental section for details).24, 41, 42 The 
following step of oxidation of complex 1 was performed with 
several oxidizing agents in order to prepare different Pt(IV) 
synthons, potentially useful for further coupling reactions 
(Scheme 1).36, 43-48 Surprisingly, the most common reaction 
conditions failed to get the expected final products. 
Iodobenzene dichloride36 and N-chlorosuccinimide45 with both 
traditional and microwave-assisted heating gave no oxidation at 
all. The use of peroxyacetic acid led to the formation of up to 
5% of the acetato-hydroxido Pt(IV) product 2A. Only H2O2 was 
efficient in oxidizing complex 1, but the results were strongly 
dependent on the reaction conditions. When hydrogen 
peroxide and acetonitrile were used to generate the reactive 
peroxyacetimidic acid,46, 47 only 12% oxidation of 1, to obtain 
the acetylamido-hydroxido Pt(IV) complex 2B, was observed. 
Syntheses in ethanol with large excess H2O2 to get the ethoxido-
hydroxido derivative 2C gave no reaction with traditional 
heating and only up to 15% of oxidized product with microwave 
heating. When acetic acid was used as a solvent, H2O2 was 
partially successful to give 2A. Traditional heating (at 30 °C or 
50 °C) with 50:1 excess 50% aqueous H2O2 from 1.5 to 48 h gave 
up to 50% of oxidized product in the milder conditions, whereas 
high temperature for a long time led to about 15% of the 
diacetato product 2D. On the contrary, the microwave-assisted 
synthesis gave 2A by heating 1 at 70 °C for 5 min with 50:1 
excess 50% aqueous H2O2. Under these conditions, 50% of 1 was 
oxidized, and this value did not significantly increase by 
increasing both excess H2O2 and/or reaction time. 
 As 2A was the most successful derivative at this stage of the 
work, its purification was attempted. The chloride counter ion 
was exchanged with hexafluorophosphate by using an anion 
exchange resin to more easily precipitate it. A further step on 
resin was used to re-introduce chloride counter ions to gain in 
water solubility. However, the final product did not reach purity 
higher than 70%, and, for this reason, 2A was abandoned. 
When water was used as a solvent, neither mild (i.e. room 
temperature, 5:1 excess 35% aqueous H2O2, overnight) nor 
strong (i.e. 70 °C, 22:1 excess 35% aqueous H2O2, overnight) 
traditional methods resulted in oxidation of 1.43, 44 On the 
contrary, microwave-assisted reaction at 70 °C in 50% aqueous 
H2O2 for 2 h was successful in the quantitative formation of 2 
(see experimental section for details). For this reason, 2 was the 
chosen intermediate for the following work. 
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Scheme 1. Summary of the attempted oxidation reactions of 1. The heating was performed with traditional hot plates, except where otherwise indicated (MW = microwave). 
DFT Calculations 
The eŶthalpǇ chaŶge foƌ ƌeactioŶ ͞Pt(II)͟ + H2O2  ͟Pt(IV)(OH)2͟ 
was calculated in the case of cisplatin and complex 1. Two other 
complexes were added in the calculations, i.e. [PtCl2(dach)] 
(dach = cyclohexane-1R,2R-diamine) and [PtCl(dien)]+, for 
coŵpaƌisoŶ ǁith ͞PtCl2N2͟ aŶd ͞PtClN3͟ coŶtaiŶiŶg aŶ aliphatic 
chelating ligands. DFT calculations (see experimental section for 
details) predict similar values for cisplatin, [PtCl2(dach)] and 
[PtCl(dien)]+ (H = -170, -194 and -184 kJ mol-1, respectively), 
but a much smaller negative H for 1 (-92 kJ mol-1). These data 
support the lower reactivity of 1 with hydrogen peroxide. On 
the contrary, [PtCl2(dach)] is usually oxidized in the same 
conditions of cisplatin44, 49 and [PtCl(dien)]+ can be easily 
oxidized with 5:1 excess 35% aqueous H2O2 at room 
temperature overnight (50% of oxidized product). To seek 
explanation for this behaviour, frontier orbitals were examined 
(Fig. 2): comparison of 1 with [PtCl(dien)]+ shows that HOMOs 
are similar in form and energy, but that the LUMO of 1 is 
delocalized over the terpy ligand, with very little density at Pt 
and none in the Pt—Cl bond, unlike in [PtCl(dien)]+ where the 
LUMO has large contributions from Pt d-orbital and the Pt—Cl 
bond. 
 
Fig. 2. HOMO and LUMO energies (au) and isosurface plots (at 0.04 au level) for cisplatin, 
[PtCl2(dach)], [PtCl(dien)]+ and 1. 
Functionalization of 2 in the axial position and coupling with silica 
nanoparticles 
  
A subsequent synthetic step consisted of functionalization of 2 
in the axial position/s. Succinic and glutaric anhydrides were 
chosen to introduce a linker necessary for further reaction with 
DTD vectors. These anhydrides generate two carboxylic groups, 
one of which reacts with an axial OH of 2, and the other one 
remaining free for further conjugation. A 5:1 excess of succinic 
or glutaric anhydride (70 °C, overnight in DMF) gave no 
substitution reactions on 2, but caused its reduction to 1. A 
decrease in temperature (40 °C) led to different results: with 
glutaric anhydride, 15% of monoglutarato Pt(IV) product was 
obtained, together with partial reduction of 2, whereas with 
succinic anhydride 75% of monosuccinato complex 3 was 
obtained (see experimental section for details). As 3 gave the 
best compromise in terms of yield and purity, the final step was 
limited to it. 
 Nonporous silica nanoparticles (SNPs) with an external shell 
containing primary amino groups were chosen as DTD vector to 
transport the Pt(IV) antitumor prodrug. Silica nanoparticles 
have attracted significant interest because of their acceptable 
biocompatibility, low cost large-scale synthesis, easy control of 
surface properties, and the possibility to modify the external 
shell with chemical functionalities needed to introduce the 
Pt(IV) moiety. Spherical SNPs containing the 3-aminopropyl arm 
were produced according to literature methods (relevant 
features: amino group density = 0.283 mmol NH2 g−1 SNPs, 
dynamic light scattering diameter = 125Ϯ Ŷŵ, ζ poteŶtial = 
532 mV).39 The SNPs were loaded with 3, after activation of 
the pendant carboxylic group with the common EDC/NHS (EDC 
= N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide, NHS = N-
hydroxysuccinimide) coupling strategy, through the formation 
of amide bonds to form conjugate 4. The Pt content in 4 was 
evaluated by inductively coupled plasma optical emission 
spectroscopy (ICP-OES) and the results indicated about 2% of 
coupling, i.e. 6.1 mol Pt g-1 SNPs. The complete series of 
reactions from 1 to 4 is reported in Scheme 2. 
 
 
Scheme 2. Sketch of the complete series of reactions from 1 to 4. EDC = N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide, NHS = N-hydroxysuccinimide; grey balls represent amino-
functionalized nonporous silica nanoparticles (SNPs). 
In vitro tests 
 Compounds 1, 2 and 4 were tested on human ovarian cancer 
cells A2780 and two cell lines derived from human malignant 
pleural mesothelioma (MPM), a very difficult to treat tumor 
(sarcomatoid MM98 cell line and its cisplatin-resistant MM98R 
subline). The reference drug cisplatin was added for comparison 
purposes. The results are reported in Table 1 and Fig. 3. 
Table 1. Cytotoxicity (IC50), resistance factor (RF), and accumulation ratio (AR) measured for cisplatin, compounds 1 and 2, and conjugate 4, respectively. Data are means ± standard 
deviations of at least three independent replicates. 
Compounds 
IC50 [µM]a 
RFc 
ARd 
A2780 MM98 MM98R A2780 MM98 
Cisplatin 0.5± 0.1b 3.2 ± 1.0b 19.4 ± 2.8b 6.1 1.4 ± 0.6e 2.71±0.18 
1 2.80±0.25 5.41±2.09 4.11±0.66 0.76 0.34±0.03 0.43±0.13 
2 7.01±0.56 10.5±0.1 8.09±0.91 0.77 0.86±0.69 0.17±0.05 
4 0.74±0.05 4.53±0.45 5.78±0.74 1.3 36.9±14.9 57.8±4.5 
a IC50 data were obtained after 72 h of treatment of A2780 ovarian cancer, MM98 malignant pleural mesothelioma and its cisplatin resistant subline MM98R cells; b from 
ref. 50; c RF = IC50 (MM98R) / IC50 (MM98); AR = ratio between the intracellular and the extracellular Pt concentration (cells were treated for 4 h with 10 µM Pt 
concentrations); e from ref. 51. 
 
  
 
Fig. 3. Comparison between IC50 values of cisplatin, compounds 1 and 2, and conjugate 
4. See Table 1 for details. 
The Pt(II) precursor 1 was less active than cisplatin except for 
the cisplatin-resistant MM98R cells, where it maintained about 
the same activity shown on sensitive MM98 cells (see resistance 
factor, RF, i.e. the ratio between IC50 on MM98R and MM98, 
respectively). In the oxidized form 2 the activity was uniformly 
lowered. In the case of the conjugate 4, the activity on A2780 
cells was only 4 times better than that of 1 and almost the same 
on MM98 and MM98R cells. Cellular accumulation of all four 
compounds was evaluated by means of the intracellular Pt 
content after 4 h of treatment and expressed as accumulation 
ratio (AR, i.e. the ratio between the intracellular and the 
extracellular Pt concentration). The results in Table 1 show that 
the SNPs are highly effective for accumulation of Pt into cells 
(more than 100 times increase in AR from 1 to 4).38, 39 These 
data would suggest an increase in activity from 1 to 4 that, 
surprisingly, does not occur. 
 In the attempt to explain these results, the solution behavior 
and reduction properties of 1 and 3 (i.e. the Pt(II) precursor and 
the complex conjugated to the SNPs, respectively) were 
investigated. The stability in solution of 1 and 3 was studied in 
HEPES buffer (HEPES = 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, pH = 7.5) at 37 °C with HPLC-MS 
technique. 1 easily underwent hydrolysis with the loss of one 
chloride (about 50% decrease of peak area of 1 in 15 min)17 and 
this is in agreement with the previously reported propensity to 
the loss of the ligand trans to terpy in this kind of complexes.27 
On the contrary, 3 was hydrolyzed with the loss of the succinato 
ligand in longer times (about 50% decrease of peak area of 3 in 
24 h). 3 was also reacted with a 10-fold excess of ascorbic acid, 
as the simplest model of bio-reductant, in HEPES buffer. The 
results indicated that 3 is easily reduced (about 50% of peak 
area decrease in 20 min); this data is consistent with the 
difficulties in the oxidation of 1 and in the synthesis of 3 often 
accompanied by reduction. 
 The fast reduction of 3 should guarantee the release of the 
Pt(II) metabolite from the conjugate 4. However, AR data 
showed high accumulation of Pt due to the endocytosis of 4 
without the expected corresponding increase in activity with 
respect to 1. The propensity to hydrolysis of 1, i.e. the Pt(II) 
metabolite of 4, could explain such strange behavior. Therefore, 
to unravel the mystery, complex 1 was dissolved and 
maintained for 4 h in an aqueous suspension of the SNPs. After 
washing and mineralization, the Pt content on the SNPs was 
measured, resulting in the conjugation of 3.9% of the total 
available amino groups (11.0 mol Pt g−1 SNPs). The data 
support the hypothesis that conjugate 4 may release 1 upon 
reduction in vitro. After hydrolysis, the aquo derivative of 1 (i.e. 
[Pt(H2O)(terpy)]2+) could ͞ƌe-cooƌdiŶate͟ the fƌee aŵiŶo gƌoups 
of the SNPs, and, in turn, it can be retained, at least in part, by 
the nanoparticles as Pt(II) complex. In the resulting tetraamine 
form, the Pt(II) complex conjugated to the SNPs is no longer able 
to exert its antiproliferative activity. Furthermore, even though 
the trans orienting effect of terpy could, at least in part, cause 
the release of hydrolyzed 1 from the amine-decorated 
nanoparticles, this complex can re-coordinate the SNPs again. 
Experimental section 
General procedures 
K2[PtCl4] (Johnson Matthey and Co.) and all other chemicals (Sigma 
Aldrich) were used without further purification. Water was purified 
(18 M cm) using a standard Milli-Q system (Millipore, Bedford, MA, 
USA). 
 The reactions under microwave irradiation were performed 
by using a CEM Discover® SP System equipped with a focused 
single mode and self-tuning cavity, an air cooling system, an 
automated power control based on temperature feedback, 
supplying power in 1 W increments from 0 to 300 W. 
The NMR spectra were measured on a NMR-Bruker Avance III 
spectrometer operating at 500 MHz (1H), 125.7 MHz (13C) and 107.2 
MHz (195Pt with a spectral window of 2000 ppm), respectively, and a 
JEOL Eclipse Plus spectrometer operating at 400 MHz (1H), 100.6 MHz 
(13C) and 86.0 MHz (195Pt, with a spectral window of 2000 ppm), 
respectively. 1H and 13C NMR chemical shifts were reported in parts 
per million (ppm) referenced to solvent resonances. 195Pt NMR 
spectra were recorded using a solution of K2PtCl4 in saturated 
aqueous KCl as the external reference. The shift for K2PtCl4 was 
adjusted to -1628 ppm from Na2PtCl6 ( = 0 ppm). 
RP-HPLC and mass analysis were performed using a Waters 
HPLC-MS instrument equipped with Alliance 2695 separations 
module, 2487 dual lambda absorbance detector and 3100 mass 
detector. Chromatographic analyses were carried out using a 
C18 Phenomenex Phenosphere-NEXT (5-m, 2504.6 mm ID) 
column. The mobile phase employed was a 70/30 (for 1 and 2) 
or 90/10 (for 3) mixture of 15mM formic acid / methanol; the 
flow rate was 0.5 mL/min and the UV-visible detector was set at 
210 nm. Electrospray ionization mass spectra (ESI-MS) were 
obtained setting the source and desolvation temperatures to 
150 °C and 250 °C, respectively, and using nitrogen both as a 
drying and as a nebulizing gas. The cone and the capillary 
voltages were usually 30 V or 20 V and 2.70 kV, respectively. 
Quasi-molecular ion peaks [M+H]+ or [M-H]- peaks were 
assigned on the basis of the m/z values and of the simulated 
isotope distribution patterns. 
  
 Mineralization of Pt-loaded SNPs was performed using a 
microwave-assisted acid digestion apparatus Milestone Start D 
(Milestone Srl, Sorisole, Italy) with internal temperature sensor. 
Platinum was quantified by inductively coupled plasma-optical 
emission spectrometry (ICP-OES, Spectro Genesis, Spectro Analytical 
Instruments, Kleve, Germany) equipped with a crossflow nebulizer, 
or by inductively coupled plasma-mass spectrometry (ICP-MS, 
Thermo Optek X Series 2). A platinum standard stock solution of 1000 
mg L-1 was diluted in 1.0% v/v nitric acid to prepare calibration 
standards. To quantify the platinum concentration by ICP-OES, the Pt 
299.797 nm line was selected. Instrumental settings for ICP-MS were 
optimized to yield maximum sensitivity for platinum. For quantitative 
determination, the most abundant isotopes of platinum and indium 
(used as internal standard) were measured at m/z 195 and 115, 
respectively. 
 
Synthesis of (SP-4-2)-dichlorido(cycloocta-1,5-diene)platinum(II), 
[PtCl2(cod)] 
[PtCl2(cod)] was synthesized according to literature 
procedures.24, 41 In particular, potassium tetrachloroplatinate(II) 
(1.00 g, 2.41 mmol) was dissolved in 16 mL of ultrapure water 
and the red solution was filtered to remove possible solid 
residues. Then, 24 mL of glacial acetic acid and cycloocta-1,5-
diene (1.00 mL, 8.15 mmol) were added and the mixture was 
magnetically stirred for 2 h at 90 °C, in the dark. During this 
time, the solution turned from red to pale yellow and a white 
solid precipitated. When significant changes were no longer 
observed, three quarter of the solvent was removed under 
reduced pressure and the white solid was separated by 
centrifugation, washed with ultrapure water, ethanol and 
diethyl ether and then dried in vacuo. Yield: 703 mg, 1.88 mmol, 
78.0%. 1H-NMR (500 MHz, CDCl3), δ: 2.27 and 2.71 (m, 8H, -CH2), 
5.61 (m, 4H, -CH) ppm. 13C-NMR (500 MHz, CDCl3), δ: 31.0 (-
CH2), 100.2 (-CH) ppm. 195Pt-NMR (500 MHz, CDCl3), δ: -3342 
ppm. 
 
Synthesis of (SP-4-2)-chlorido(2,2':6',2''-terpyridine)platinum(II) 
chloride (1) 
Complex 1 was synthesized according to literature 
procedures.42 Briefly, [PtCl2(cod)] (154 mg, 0.412 mmol) was 
suspended in 10 mL of ultrapure water. Then, terpy (101 mg, 
0.433 mmol) was added to the mixture, which was magnetically 
stirred for 30 min at 70 °C. The red mixture was dried under 
reduced pressure and the red residue was washed with diethyl 
ether and then dried in vacuo. Yield: 170 mg, 0.341 mmol, 
82.7%. 1H-NMR (400 MHz, MeOD-d4), δ: 7.79 (m, H2, H14, 2H), 
8.40 (m, H1, H15, H3, H13, H7, H9, 6H), 8.47 (m, H8, 1H), 8.82 
(m, H4, H12, 2H) ppm. 13C-NMR (100.6 MHz, MeOD-d4), δ: 124.1 
(C1, C15), 125.3 (C7, C9), 128.7 (C2, C14), 141.7 (C8), 142.4 (C3, 
C13), 151.4 (C4, C12), 154.9 (C5, C11), 158.8 (C6, C10) ppm. 
195Pt-NMR (86.0 MHz, MeOD-d4), δ: -2734 ppm. ESI-MS: calcd 
for C15H11Cl2N3Pt [M] 499 m/z, found (positive ion mode) 464 
m/z [M-Cl]+. 
 
Synthesis of (OC-6-32)-chloridodihydroxido(2,2':6',2''-
terpyridine)platinum(IV) chloride (2) 
Complex 1 (40.0 mg, 0.0801 mmol) was dissolved in 50% w/w 
aqueous hydrogen peroxide (2.00 mL, 35.2 mmol) in a 
microwave vessel. The vessel was capped and introduced into 
the microwave cavity. The microwave unit heated the vessel 
content to 70 °C over a 5-min ramp period and then maintained 
this temperature for 2 h while stirring the mixture with a 
magnetic bar; the power was automatically set at 50 W. After 
heating, the vessel was allowed to cool to room temperature 
before removing it from the cavity. The solvent was removed 
under reduced pressure and the addition of acetone/diethyl 
ether allowed one to get a yellow solid, that was washed with 
diethyl ether and then dried in vacuo. Yield: 35.0 mg, 0.0656 
mmol, 81.9%. 1H-NMR (500 MHz, D2O), δ: 8.16 (t, H2, H14, 2H, 
3J = 6.7 Hz), 8.64 (t, H3, H13, 2H, 3J = 7.8 Hz), 8.73 (d, H7, H9, 2H, 
3J = 7.8 Hz), 8.81 (s, H1, H8, H15, 3H), 9.35 (d, H4, H12, 2H, 3J = 
5.6 Hz) ppm. 13C-NMR (125.7 MHz, D2O), δ: 126.9 (C1, C15), 
128.0 (C7, C9), 130.6 (C2, C14), 144.9 (C3, C13), 146.0 (C8), 
151.6 (C4, C12), 152.2 (C5, C11), 156.7 (C6, C10) ppm. 195Pt-
NMR (107.2 MHz, D2O), δ: 387 ppm. ESI-MS: calcd for 
C15H13Cl2N3O2Pt [M] 533 m/z, found (positive ion mode) 498 
m/z [M-Cl]+. 
 
Synthesis of (OC-6-43)-(4-
carboxypropanoato)chloridohydroxidoplatinum(IV) (3) 
A solution of succinic anhydride (46.9 mg, 0.469 mmol) in 1 mL 
of DMF was added to a suspension of complex 2 (50.0 mg, 
0.0938 mmol) in 2 mL of DMF and the reaction was carried out 
at 40 °C overnight. The solvent was then removed under 
reduced pressure and an orange solid was precipitated by the 
addition of acetone/diethyl ether. It was purified with an 
anionic exchange resin (Amberlite® IRA-400(OH) Supelco, in 
which the hydroxido groups were replaced by chloride anions) 
in order to remove free succinate and to introduce chlorides as 
counter ions. The resulting solution was dried under reduced 
pressure and the residue was washed with methanol and dried 
in vacuo. Yield: 44.8 mg, 0.0707 mmol, 75.4%. 1H-NMR (500 
MHz, D2O), δ: 2.62 (s, H17, H18, 4H), 8.13 (m, H2, H14, 2H), 8.60 
(t, H3, H13, 2H, 3J = 7.9 Hz), 8.69 (d, H7, H9, 2H, 3J = 7.9 Hz), 8.75 
(s, H1, H8, H15, 3H), 9.34 (d, H4, H12, 2H, 3J = 5.7 Hz) ppm. 13C-
NMR (125.7 MHz, D2O), δ: 29.9 (C17, C18), 126.5 (C1, C15), 
127.6 (C7, C9), 130.3 (C2, C14), 144.9 (C3, C13), 146.0 (C8), 
151.7 (C4, C12), 152.8 (C5, C11), 157.3 (C6, C10), 177.2 (C19), 
180.3 (C16) ppm. 195Pt-NMR (107.2 MHz, D2O), δ: 524 ppm. ESI-
MS: calcd for C19H17Cl2N3O5Pt [M] 633 m/z, found (positive ion 
mode) 598 m/z [M-Cl]+. 
 
Loading of complex 3 on silica nanoparticles (conjugate 4) 
A mixture of 3 (12.1 mg, 0.0191 mmol) and N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC, 4.4 mg, 0.0229 mmol) in 1 ml of ultrapure water was 
magnetically stirred for 5 min at room temperature, then N-
hydroxysuccinimide (NHS, 2.6 mg, 0.0229 mmol) was added and 
the reaction was performed for 30 min. In the meanwhile, an 
  
ethanol suspension of amino-functionalized silica nanoparticles 
SNPs (13.67 mg mL−1), prepared according to previously 
published procedures,39 was centrifuged to remove the solvent, 
washed with ultrapure water, centrifuged and resuspended in 
water. The resulting suspension of SNPs was added to the 
previously prepared solution of activated 3 and the mixture was 
magnetically stirred for 2 h at room temperature to get 
conjugate 4. The product was collected by centrifugation (10 
min, 10000 rpm), washed several times with water and, then, 
resuspended in ethanol. 
 
Quantification of the platinum content on conjugate 4 
After microwave acid mineralization of conjugate 4, the Pt 
content was determined by means of ICP-OES. In particular, the 
ethanol suspension of 4 was centrifuged to remove the alcohol 
and the solid portion was dried. Then, 2-3 mg of dry product 
ǁeƌe iŶtƌoduced iŶto Ƌuaƌtz cuǀettes, togetheƌ ǁith 800 μL of 
70% w/w HNO3 aŶd Ϯ00 μL of ϯϱ% ǁ/ǁ aƋueous hǇdƌogeŶ 
peroxide. These devices were put into a closed vessel in the 
microwave oven (200 °C, 45 min, 1200 W microwave power). 
The vessel was then cooled to room temperature and the 
cuvettes were pulled out: their content was transferred into 
marked flasks using 1% v/v HNO3 and sonicated for 1 h at 60 °C. 
After centrifugation (5 min, 10000 rpm) to remove the silica 
residue, the quantification of the Pt content of the supernatant 
was measured by ICP-OES. The results indicated a Pt loading of 
6.23 mol Pt g−1 NPs, corresponding to the conjugation of 2.2% 
of the total available amino groups (0.283 mmol NH2 g-1 SNPs). 
 
Stability and reactions in solution 
The solution behavior of complexes 1 and 3 (0.5 mM) was 
studied in 2 mM HEPES buffer (HEPES = 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid, pH = 7.5) at 37 °C. The reduction 
of complex 3 (0.5 mM) with ascorbic acid (ascorbic acid:Pt molar 
ratio = 10:1) was studied in 2 mM HEPES at 37 °C. All these 
reactions were followed by monitoring the decrease of the area 
of the chromatographic peaks of the Pt complexes in HPLC-UV-
MS and the increase of possible new peaks. The mobile phase 
was a mixture of 15 mM aqueous HCOOH and CH3OH in ratios 
of 70/30 for 1 and 90/10 for 3. 
 
DFT calculations 
All DFT calculations were carried out using Gaussian0952 at the 
B3LYP53, 54 level, using a basis set consisting of LANL2DZ on Pt55, 
56 and 6-31G(d)57 on all remaining atoms. All species were fully 
optimized without any symmetry constraint, and confirmed as 
minima by harmonic frequency calculations. The same 
calculations were used to estimate thermal corrections to 
electronic energy to obtain enthalpy changes, and to extract 
HOMO/LUMO plots. 
 
Cytotoxicity 
Compounds 1, 2 and 4 were tested on three cancer cell lines: 
the human ovarian carcinoma cell line A2780, purchased from 
ECACC (European Collection of Cell Cultures, UK), a primary 
malignant pleural mesothelioma (MPM) cancer cell line, derived 
of pleural effusion of previously untreated patients suffering 
from MPM, namely MM98 (sarcomatoid), and on a cisplatin-
resistant cell line derived from wild type MM98 by exposure to 
sub-lethal concentrations of cisplatin for several months, called 
MM98R.58 The last two cell lines were obtained from the 
Hospital of Alessandria (Pathology Unit). 
 A2780 were grown in RPMI1640, whereas DMEM (Sigma-
Aldrich) was used for MPM cells. All media were supplemented 
with L-glutamine (2 mM), penicillin 100 IU mL-1, streptomycin 
(100 mg L-1) and 10% fetal bovine serum (FBS). Cell culture and 
the treatments were carried on at 37 °C in a 5% CO2 humidified 
chamber. Cell were challenged with the compounds under 
study for 72 h continuous treatment (CT). 
 Cisplatin and complex 1 were dissolved in 0.9% w/v NaCl 
aqueous solution brought to pH 3 with HCl (final stock 
concentration 1 mM), complex 2 was dissolved in water (final 
stock concentration 5 mM), whereas conjugate 4 was 
suspended in absolute ethanol (final Pt stock concentration 
0.125 mM). The mother solutions were diluted in complete 
medium to required concentration range. In the case of co-
solvent the total absolute ethanol concentration never 
exceeded 0.2% (this concentration was found to be non-toxic to 
the cell tested). 
 To assess the growth inhibition of the compounds under 
investigation, a cell viability test, i.e. the resazurin reduction 
assay was used.59 Briefly, cells were seeded in black sterile 
tissue-culture treated 96-well plates. At the end of the 
treatment, viability was assayed by 10 g mL-1 resazurin (Acros 
Chemicals, France) in fresh medium for 1 h at 37 °C, and the 
amount of the reduced product, resorufin, was measured by 
means of fluorescence (excitation 535 nm, emission 595 nm) 
with a Tecan Infinite F200Pro plate reader (Tecan Austria). In 
each experiment, cells were challenged with the drug 
candidates at different concentrations and the final data were 
calculated from at least three replicates of the same experiment 
performed in triplicate. The fluorescence of 8 wells containing 
medium without cells were used as blank. Fluorescence data 
were normalized to 100% cell viability for non-treated cells. Half 
inhibiting concentration (IC50), defined as the concentration of 
the drug reducing cell viability by 50%, was obtained from the 
dose-response sigmoid using Origin Pro (version 8, Microcal 
Software, Inc., Northampton, MA, USA). 
 
Cellular uptake 
Cells under investigation (2×106) were seeded in 25 cm2 flasks 
and treated for 4 h with 10 µM of the complexes under 
investigation (1 M in the case of 4) in complete medium. After 
4 h, cells were washed two times with PBS (1X), detached from 
the flask using 0.05% Trypsin 1X + 2% EDTA (HyClone, Thermo 
Fisher) and harvested in fresh complete medium. An automatic 
cell counting device (Countess®, Life Technologies), was used to 
measure the cell number and the mean diameter from every 
cell count. About 5×106 cells were transferred into a borosilicate 
glass tube and centrifugated at 1100 rpm for 5 min at room 
  
temperature. The supernatant was carefully removed by 
aspiration; in order to limit the cellular loss, about 200 µL of the 
supernatant were left. Cellular pellets were stored at -80 °C 
until mineralization. After defrosting, 70% w/w HNO3 was 
added and left 1 h at 60 °C in an ultrasonic bath. Before the 
measurement, the HNO3 was diluted to a final 3% v/v 
concentration. Platinum determination was performed by 
inductively coupled plasma-mass spectrometry (ICP-MS, 
Thermo Optek X Series 2). Instrumental settings were optimized 
to yield maximum sensitivity for platinum. For quantitative 
determination, the most abundant isotopes of platinum and 
indium (used as internal standard) were measured at m/z 195 
and 115, respectively. 
 The level of Pt found in cells after the treatment was 
normalized to the cell number and the cellular volume, 
calculated from the actual mean cell diameter measured for 
every sample, to obtain the intracellular Pt concentration. The 
ratio between the intracellular and the known extracellular 
concentration of offered Pt is defined accumulation ratio, AR.60 
 
Conclusions 
In summary, this research has shown that, differently from Pt(II) 
complexes containing aliphatic di- or triamines, the oxidation of 
Pt(terpy) compounds is much more difficult and leads to Pt(IV) 
complexes somewhat problematic to handle. In its intermediate 
form 2, the Pt(IV)-terpy was reasonably easy to use in the 
functionalization of silica nanoparticles. Surprisingly, the 
cytotoxic features observed in similar Pt(IV)-SNPs conjugates 
were not repeated, despite increased cellular accumulation by 
endocytosis. The possible explanation of such unsatisfactory 
result may be traced back to the reactivity of the Pt(II) 
metabolite, obtained in vitro after reduction from 4, with the 
free amino groups of the SNPs. However, the biological features 
of the conjugate 4 and that of the Pt(II)-terpy precursor 1 
remain interesting in the case of cisplatin-resistant cell lines. 
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